vTv Therapeutics Inc Class A VTVT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
vTv Therapeutics Announces Oral Presentation at Breakthrough T1D Clinical and Research Congress 2026
-
VTv Therapeutics Gets FDA Orphan Drug Designation for HPPD in Sickle Cell Disease
-
vTv Therapeutics Announces FDA Orphan Drug Designation for HPPD in Sickle Cell Disease
-
vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026
-
vTv Therapeutics Announces Completion of Enrollment in Phase 3 CATT1 Study of Cadisegliatin in Type 1 Diabetes (T1D)
-
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
-
vTv Therapeutics to Participate in September Investor Conferences
-
vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $27.16
- Day Range
- $25.35–27.95
- 52-Week Range
- $19.98–44.38
- Bid/Ask
- $0.00 / $0.00
- Shares Outstanding
- 3.95M
- Market Cap
- $101.02M
- Volume/Avg
- 21,622 / 58,938
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 8.72
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 26
- Website
- https://www.vtvtherapeutics.com
Valuation
|
Metric
|
VTVT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.30 |
Price/Sales | 8.72 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
VTVT
|
|---|---|
Quick Ratio | 12.35 |
Current Ratio | 12.48 |
Interest Coverage | — |
Quick Ratio
VTVT
Profitability
|
Metric
|
VTVT
|
|---|---|
Return on Assets (Normalized) | −1.49% |
Return on Equity (Normalized) | −1.95% |
Return on Invested Capital (Normalized) | −6.70% |
Return on Assets
VTVT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|VLtqTZ | LOCK|h$TP | $133B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|VkfF>^? | LOCK|$njTW | $83B | |||
| Moderna Inc
MRNA
| LOCK|%Gd<^pJ | LOCK|#Z | $80B | |||
| argenx SE ADR
ARGX
| LOCK|gSxf!B | LOCK|N># | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$bxGhd | LOCK|Hb | $45B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|hS<$S? | LOCK|<RFk< | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|f>?sd^< | LOCK|hv?$ | $28B | |||
| Incyte Corp
INCY
| LOCK|sRbmcP | LOCK|>p | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|sJ&D?Gg | LOCK|%q | $22B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&C$###j | LOCK|&qW | $14B |
United States